Clinical trial Recruiting at 2 sites Interventional Ages 19 and up

Enhanced recovery (ERAS) after minimally invasive stomach cancer surgery

Official title: Effectiveness of Enhanced Recovery After Surgery (ERAS) on Postoperative Recovery After Minimally Invasive Gastrectomy: A Multi-center Open-labeled Randomized Controlled Study

Run by Seoul National University Hospital · NCT06984952 · Data updated 2026-11-12

This project tests whether an enhanced recovery (ERAS) program helps people recover faster and leave the hospital sooner after minimally invasive stomach cancer surgery.

More Enhanced Recovery After Surgery trials

Quick facts

Study typeInterventional
Ages19 Years and up
SexAll
Enrollment308 (estimated)
SponsorSeoul National University Hospital
Academic / other
Locations10 sites (Busan and 9 other locations)
StatusRecruiting
StartedJune 13, 2025
Main results expectedDecember 31, 2028
Study endsMarch 31, 2029
Registry record updatedSeptember 5, 2025
Trial IDNCT06984952 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 19 or older scheduled for elective laparoscopic or robotic gastrectomy for gastric cancer with ASA physical status I–III who can provide informed consent and complete patient-reported measures.

Probably not a fit

Patients who require additional organ resections, have prior upper abdominal surgery (other than cholecystectomy), or have known hypersensitivity to the study analgesics may not be eligible or likely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, randomized, open-label, multicenter trial compares a structured ERAS protocol with conventional perioperative care in adults undergoing elective laparoscopic or robotic gastrectomy for gastric cancer. Patients were randomized 1:1 (154 per group) to receive either the ERAS pathway or usual care, with ERAS elements including preoperative carbohydrate loading, shorter perioperative fasting, and multimodal opioid-sparing analgesia. The primary outcome is the proportion of patients who meet standardized discharge criteria at 9:00 AM on postoperative day 4, and secondary outcomes include EQ-5D-5L quality-of-life scores, pain at rest and with coughing, I-FEED gastrointestinal function, postoperative nausea and vomiting, major complications (Clavien-Dindo), and length of hospital stay. The open-label design and multiple high-volume centers aim to generate results that reflect real-world implementation of ERAS in minimally invasive gastrectomy.

Why it matters

Potential benefit: If successful, the ERAS protocol could let more patients meet discharge criteria earlier, reduce pain and nausea, and shorten hospital stays after minimally invasive gastrectomy.

How similar studies have gone: ERAS programs have improved recovery and shortened hospital stays in colorectal surgery and have shown benefit in several gastric surgery reports, although protocols and effect sizes vary across centers.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged ≥19 years scheduled to undergo elective laparoscopic or robotic gastrectomy for gastric cancer
* American Society of Anesthesiologists physical status classification I to III
* Ability to provide written informed consent, demonstrate understanding of the study protocol, and complete patient-reported outcome measures appropriately

Exclusion Criteria:

* Requirement for resection of organs other than the stomach during surgery (except for cholecystectomy)
* History of upper abdominal surgery (except for cholecystectomy)
* Known hypersensitivity to fentanyl, ropivacaine, acetaminophen, or non-steroidal anti-inflammatory drugs
* Determined by the investigator or study personnel to be otherwise unsuitable for participation in the study

Where it's running

  • Dongsan Hospital, Keimyung University School of Medicine
    Daegu, South Korea
    Recruiting
  • Seoul National University Hospital
    Seoul, South Korea
    Recruiting
  • Pusan National University Hospital
    Busan, South Korea
    Not yet recruiting
  • Chungnam National University Hospital
    Daejeon, South Korea
    Not yet recruiting
  • National Cancer Center
    Goyang, South Korea
    Not yet recruiting
  • Seoul National University Bundang Hospital
    Seongnam, South Korea
    Not yet recruiting
Show 4 more locations
  • Seoul St. Mary's Hospital
    Seoul, South Korea
    Not yet recruiting
  • Severance hospital
    Seoul, South Korea
    Not yet recruiting
  • SMG-SNU Boramae Medical Center,
    Seoul, South Korea
    Not yet recruiting
  • Ajou University School of Medicine
    Suwon, South Korea
    Not yet recruiting

Study contacts

  • Principal investigator: Do Joong Park, MD, PhD — Seoul National University Hospital
  • Study coordinator: Hojin Lee, MD, PhD
  • Email: hjpainfree@snu.ac.kr
  • Phone: 82-2-2072-2467

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.